Revvity Expands Signals AI With Anthropic Claude Integration
RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.
Revvity Launches Signals AI to Advance Scientific R&D Workflows
RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.
Revvity to Report Q1 Earnings: What's in Store for the Stock?
RVTY heads into Q1 earnings with Diagnostics strength and Life Sciences stabilization, but China pressures and weak academic demand may temper near-term growth.
RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data
Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.
Revvity Gains on Diagnostics Strength, Faces China Headwinds
RVTY gains from strong diagnostics and software growth, but China weakness, soft demand, and margin pressures temper its near-term outlook.
